AVALA RES
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
AVALA RES (CVJ) - Net Assets
Latest net assets as of June 2024: €13.92 Million EUR
Based on the latest financial reports, AVALA RES (CVJ) has net assets worth €13.92 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€92.77 Million) and total liabilities (€78.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €13.92 Million |
| % of Total Assets | 15.01% |
| Annual Growth Rate | -30.9% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.68 |
AVALA RES - Net Assets Trend (2020–2024)
This chart illustrates how AVALA RES's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AVALA RES (2020–2024)
The table below shows the annual net assets of AVALA RES from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €13.92 Million | -76.51% |
| 2023-06-30 | €59.26 Million | -30.20% |
| 2022-06-30 | €84.90 Million | -7.59% |
| 2021-06-30 | €91.87 Million | +50.43% |
| 2020-06-30 | €61.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AVALA RES's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13126662100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €183.39 Million | 1317.38% |
| Total Equity | €13.92 Million | 100.00% |
AVALA RES Competitors by Market Cap
The table below lists competitors of AVALA RES ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nykredit Invest Lange Obl KL A
CO:NYILOKLA
|
$113.33K |
|
Pekin Life Insurance Co
PINK:PKIN
|
$113.40K |
|
JBG SMITH PPTYS DL -01
F:JBG
|
$113.41K |
|
5N PLUS
BE:EMB
|
$113.52K |
|
GLOG11
SA:GLOG11
|
$113.11K |
|
PHOENIX BEVERAGES LTD
SEM:PBL
|
$113.07K |
|
DTF Tax Free Income Closed Fund
NYSE:DTF
|
$112.95K |
|
CLIFFS NATURAL RES
BE:CVA
|
$112.91K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AVALA RES's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 59,261,000 to 13,921,000, a change of -45,340,000 (-76.5%).
- Net loss of 51,242,000 reduced equity.
- New share issuances of 4,457,000 increased equity.
- Other factors increased equity by 1,445,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-51.24 Million | -368.09% |
| Share Issuances | €4.46 Million | +32.02% |
| Other Changes | €1.45 Million | +10.38% |
| Total Change | €- | -76.51% |
Book Value vs Market Value Analysis
This analysis compares AVALA RES's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | €0.42 | €0.00 | x |
| 2021-06-30 | €0.33 | €0.00 | x |
| 2022-06-30 | €0.24 | €0.00 | x |
| 2023-06-30 | €0.15 | €0.00 | x |
| 2024-06-30 | €0.03 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AVALA RES utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -368.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -333.32%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 6.66x
- Recent ROE (-368.09%) is below the historical average (-102.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -27.73% | -2616.94% | 0.01x | 1.25x | €-23.04 Million |
| 2021 | -27.32% | -584.74% | 0.04x | 1.11x | €-34.29 Million |
| 2022 | -31.17% | -412.85% | 0.05x | 1.64x | €-34.96 Million |
| 2023 | -57.02% | -245.26% | 0.11x | 2.18x | €-39.72 Million |
| 2024 | -368.09% | -333.32% | 0.17x | 6.66x | €-52.63 Million |
Industry Comparison
This section compares AVALA RES's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,261,324,252
- Average return on equity (ROE) among peers: -99.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AVALA RES (CVJ) | €13.92 Million | -27.73% | 5.66x | $113.22K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |